Advanced

Breast tumours following combined hormone replacement therapy express favourable prognostic factors.

Borgquist, Signe LU ; Anagnostaki, Lola; Jirström, Karin LU ; Landberg, Göran LU and Manjer, Jonas LU (2007) In International Journal of Cancer 120(10). p.2202-2207
Abstract
t

The aim of the present study was to evaluate the association between different types of hormone replacement therapy (HRT) and risk of specific breast cancer subgroups. A population-based prospective cohort study including 12,583 peri- or postmenopausal women were followed using record-linkage with national cancer registries. During an average follow-up of 4.5 years, 332 cases of invasive breast cancer were diagnosed. Tumour samples were available from 283 cases. These tumours were re-evaluated according to histological type, grade, and mitotic index. Evaluation of tumours included estrogen and progesterone receptor status (ER alpha, ER beta and PgR), as well as expression of Ki67, HER2, cyclin D1 and p27. The incidence of... (More)
t

The aim of the present study was to evaluate the association between different types of hormone replacement therapy (HRT) and risk of specific breast cancer subgroups. A population-based prospective cohort study including 12,583 peri- or postmenopausal women were followed using record-linkage with national cancer registries. During an average follow-up of 4.5 years, 332 cases of invasive breast cancer were diagnosed. Tumour samples were available from 283 cases. These tumours were re-evaluated according to histological type, grade, and mitotic index. Evaluation of tumours included estrogen and progesterone receptor status (ER alpha, ER beta and PgR), as well as expression of Ki67, HER2, cyclin D1 and p27. The incidence of breast cancer in current users of combined HRT (CHRT) was significantly higher than in non-users. The difference corresponded to an adjusted relative risk (95% confidence interval) of 3.01 (2.35-3.84) as obtained using a Cox's proportional hazards analysis. CHRT was associated with lobular tumours (3.48:1.99-6.10), grade I tumours (4.46:2.79-7.13) and tumours with a low mitotic index (4.35:2.99-6.34). CHRT was not related to any specific subgroup in terms of ER alpha-, ER beta- or PgR-expression. CHRT was associated with low proliferating tumours, defined by the Ki67 index (3.58:2.60-4.93), HER2 amplified tumours (4.40:1.93-10.06), low expression of the oncogene cyclin D1 (3.14:2.32-4.23) and high expression of the tumour suppressor gene p27 (3.47:2.40-5.01). Use of estrogen-alone HRT (ERT) was not associated with any statistically significant risk of breast cancer. We conclude that the use of CHRT is associated with an increased incidence of breast tumours with comparatively favourable prognostic factors. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Ki67, p27, breast cancer, hormone replacement therapy, cyclin D1
in
International Journal of Cancer
volume
120
issue
10
pages
2202 - 2207
publisher
John Wiley & Sons
external identifiers
  • wos:000245565100018
  • scopus:34147164948
ISSN
0020-7136
DOI
10.1002/ijc.22542
language
English
LU publication?
yes
id
edd09e7f-b4de-4803-be6c-6e3779ee2c43 (old id 165911)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17278089&dopt=Abstract
date added to LUP
2007-07-16 11:10:31
date last changed
2017-09-24 03:48:37
@article{edd09e7f-b4de-4803-be6c-6e3779ee2c43,
  abstract     = {t 	<br/><br>
The aim of the present study was to evaluate the association between different types of hormone replacement therapy (HRT) and risk of specific breast cancer subgroups. A population-based prospective cohort study including 12,583 peri- or postmenopausal women were followed using record-linkage with national cancer registries. During an average follow-up of 4.5 years, 332 cases of invasive breast cancer were diagnosed. Tumour samples were available from 283 cases. These tumours were re-evaluated according to histological type, grade, and mitotic index. Evaluation of tumours included estrogen and progesterone receptor status (ER alpha, ER beta and PgR), as well as expression of Ki67, HER2, cyclin D1 and p27. The incidence of breast cancer in current users of combined HRT (CHRT) was significantly higher than in non-users. The difference corresponded to an adjusted relative risk (95% confidence interval) of 3.01 (2.35-3.84) as obtained using a Cox's proportional hazards analysis. CHRT was associated with lobular tumours (3.48:1.99-6.10), grade I tumours (4.46:2.79-7.13) and tumours with a low mitotic index (4.35:2.99-6.34). CHRT was not related to any specific subgroup in terms of ER alpha-, ER beta- or PgR-expression. CHRT was associated with low proliferating tumours, defined by the Ki67 index (3.58:2.60-4.93), HER2 amplified tumours (4.40:1.93-10.06), low expression of the oncogene cyclin D1 (3.14:2.32-4.23) and high expression of the tumour suppressor gene p27 (3.47:2.40-5.01). Use of estrogen-alone HRT (ERT) was not associated with any statistically significant risk of breast cancer. We conclude that the use of CHRT is associated with an increased incidence of breast tumours with comparatively favourable prognostic factors.},
  author       = {Borgquist, Signe and Anagnostaki, Lola and Jirström, Karin and Landberg, Göran and Manjer, Jonas},
  issn         = {0020-7136},
  keyword      = {Ki67,p27,breast cancer,hormone replacement therapy,cyclin D1},
  language     = {eng},
  number       = {10},
  pages        = {2202--2207},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Breast tumours following combined hormone replacement therapy express favourable prognostic factors.},
  url          = {http://dx.doi.org/10.1002/ijc.22542},
  volume       = {120},
  year         = {2007},
}